EUVIMEDEUVIMED entdecken
Crossref

Nodal Modulator Regulates Chemo- and Radioresistance in Lung Cancer via the Chk2 Pathway

Hye Min Kim, Ju-Young Kim, Chang Geun Lee, Jie-Young Song, Jong Kuk Park, Jiyeon Ahn, Chang-Woo Lee, Seung Jin Han, Sang-Gu Hwang, Jeong-Hwa Baek

Anticancer Research · 2025

DOI: 10.21873/anticanres.17830 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Hye Min Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research Center, Dongnam Institute of Radiological & Medical Sciences, Busan, Republic of Korea. Hauptthemen laut MEDLINE: Lung Neoplasms, Checkpoint Kinase 2, Radiation Tolerance, Drug Resistance, Neoplasm.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: The limited efficacy of lung cancer treatment is partly due to the development of resistance to chemotherapy and radiotherapy. Recently, we identified Nodal modulators (NOMO1, NOMO2, and NOMO3), proteins involved in early embryonic patterning, as key factors in the radioresistance of lung cancer cells. Although NOMO proteins are highly expressed in lung cancer tissues, their roles in lung cancer have yet to be sufficiently determined. MATERIALS AND METHODS: To determine the function of NOMO, we assessed the effects of human NOMO-specific small interfering RNA (siRNA) on tumor cell viability and apoptosis. RESULTS: NOMO silencing was found to counter the chemo- and radioresistance associated with caspase-dependent apoptosis in lung cancer cells. Furthermore, antibody array results revealed that the inhibition of NOMO leads to increased phosphorylation of the checkpoint kinases Chk1 and Chk2, which modulate chemo- and radioresistance. CONCLUSION: NOMO and the Chk2 pathway are involved in chemo- and radioresistance in lung cancer, highlighting NOMO as a potential target for the development of gene therapies for the treatment of patients with lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCheckpoint Kinase 2Radiation ToleranceDrug Resistance, NeoplasmHumansApoptosisSignal TransductionCell Line, TumorCell SurvivalRNA, Small InterferingPhosphorylationGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Chk1Chk2NOMOchemoresistancelung cancerradioresistance

Substanzen

Checkpoint Kinase 2CHEK2 protein, humanRNA, Small Interfering

Autor:innen und Institutionen

  • Department of Research Center, Dongnam Institute of Radiological & Medical Sciences, Busan, Republic of Korea.
  • Department of Biological Science, Inje University, Gimhae, Republic of Korea.
  • Division of Radiation Biomedical Research, Korea Institute of Radiological & Medical Sciences, Seoul, Republic of Korea.
  • Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
  • Department of Digital Anti-Aging Healthcare, Inje University, Gimhae, Republic of Korea.
  • Division of Radiation Biomedical Research, Korea Institute of Radiological & Medical Sciences, Seoul, Republic of Korea; sgh63@kcch.re.kr.

Zitieren

APA

Kim, H. M., Kim, J. Y., Lee, C. G., Song, J. Y., Park, J. K., Ahn, J., Lee, C. W., Han, S. J., Hwang, S. G., & Baek, J. H. (2025). Nodal Modulator Regulates Chemo- and Radioresistance in Lung Cancer via the Chk2 Pathway. Anticancer Research. https://doi.org/10.21873/anticanres.17830

Vancouver

Kim HM, Kim JY, Lee CG, Song JY, Park JK, Ahn J, et al. Nodal Modulator Regulates Chemo- and Radioresistance in Lung Cancer via the Chk2 Pathway. Anticancer Research. 2025. doi:10.21873/anticanres.17830

BibTeX
@article{Kim2025,
  author = {Kim, Hye Min and Kim, Ju-Young and Lee, Chang Geun and Song, Jie-Young and Park, Jong Kuk and Ahn, Jiyeon and Lee, Chang-Woo and Han, Seung Jin and Hwang, Sang-Gu and Baek, Jeong-Hwa},
  title = {Nodal Modulator Regulates Chemo- and Radioresistance in Lung Cancer via the Chk2 Pathway},
  journal = {Anticancer Research},
  year = {2025},
  doi = {10.21873/anticanres.17830}
}
Kostenlos starten →